Active Not Recruiting PHASE2 INTERVENTIONAL 1-arm NCT03589547

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung (358)

Sponsor: Brown University

Conditions Stage III Non-small-cell Lung Cancer

Updated 11 times since 2018 Last updated: Feb 3, 2025 Started: May 13, 2019 Primary completion: Oct 31, 2025 Completion: Oct 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03589547, this PHASE2 trial focuses on Stage III Non-small-cell Lung Cancer and remains ongoing. Sponsored by Brown University, it has been updated 11 times since 2019, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

11 versions recorded

Mar 2025 — Present [monthly]

Active Not Recruiting PHASE2
Sep 2024 — Mar 2025 [monthly]

Active Not Recruiting PHASE2
Jul 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE2
Mar 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2023 — Mar 2024 [monthly]

Recruiting PHASE2

▶ Show 6 earlier versions

Mar 2022 — Feb 2023 [monthly]

Recruiting PHASE2
Sep 2021 — Mar 2022 [monthly]

Recruiting PHASE2
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE2
Feb 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jan 2019 — Feb 2020 [monthly]

Not Yet Recruiting PHASE2
Aug 2018 — Jan 2019 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brown University
Lifespan

Data source: Brown University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Providence, United States